$4450
$3560
The biopharmaceutical contract manufacturing market size is projected to reach US$ 101.05 billion by 2031 from US$ 40.99 billion in 2024. The market is expected to register a CAGR of 13.8% during 2025–2031. Advanced manufacturing technologies are emerging as a significant trend in the biopharmaceutical contract manufacturing market.
Biopharmaceutical Contract Manufacturing Market Analysis
The biopharmaceutical contract manufacturing market is witnessing substantial growth due to increasing demand for biologics, including monoclonal antibodies, gene therapies, and vaccines, which necessitates specialized manufacturing capabilities, prompting pharmaceutical companies to outsource production to contract manufacturing organizations (CMOs). Advancements in manufacturing technologies, such as continuous processing, single-use systems, and automation, enhance production efficiency and scalability, enabling CMOs to meet the complex demands of biological production. The rising inclination toward outsourcing allows companies to focus on core competencies while reducing operational costs and capital expenditures. In addition, the expansion of healthcare access in emerging markets, coupled with favorable regulatory environments, presents new opportunities for contract manufacturers to serve a broader customer base. Strategic partnerships and alliances between biopharmaceutical companies and CMOs facilitate technology transfer and process optimization, accelerating product development and commercialization timelines. These factors together contribute to the growth of the biopharmaceutical contract manufacturing market globally.
Biopharmaceutical Contract Manufacturing Market Overview
The global biopharmaceutical contract manufacturing market is accelerating owing to the rising demand for biologics, biosimilars, and complex therapies. North America leads the market with a strong presence of biopharmaceutical companies and regulatory support. Technological advancements, such as continuous manufacturing and robotics, are enhancing efficiency and scalability in production processes. Furthermore, geopolitical shifts are prompting companies to diversify supply chains, with Indian firms such as Syngene International expanding operations in the US to mitigate risks associated with reliance on Chinese manufacturing. Similarly, European CMOs are expanding capabilities in high-growth areas such as biologics, cell and gene therapies, and high-potency APIs. Countries such as Germany, France, and Switzerland continue to lead with their established infrastructure and innovation-driven ecosystems, while emerging hubs in Central and Eastern Europe, including Poland and Hungary, are gaining traction due to cost advantages and growing technical expertise. Strategic partnerships, regulatory harmonization, and supportive government policies position Europe as a diverse and competitive region for end-to-end biopharmaceutical manufacturing services.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Biopharmaceutical Contract Manufacturing Market: Strategic Insights
Market Size Value in US$ 15,735.04 million in 2021 Market Size Value by US$ 27,868.50 million by 2028 Growth rate CAGR of 8.5% from 2021 to 2028. Forecast Period 2021- 2028 Base Year 2021
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Biopharmaceutical Contract Manufacturing Market: Strategic Insights
| Market Size Value in | US$ 15,735.04 million in 2021 |
| Market Size Value by | US$ 27,868.50 million by 2028 |
| Growth rate | CAGR of 8.5% from 2021 to 2028. |
| Forecast Period | 2021- 2028 |
| Base Year | 2021 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Biopharmaceutical Contract Manufacturing Market Drivers and Opportunities
Rising Demand for Biologics Bolster Market
Biologics are the basis of modern medicine due to their increased efficacy in treating complex and chronic diseases such as cancer, autoimmune disorders, and genetic conditions. Monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins are some of the major biologics used prominently in medical services. As per the National Cancer Institute, ~20 million new cancer cases and 9.7 million cancer-related mortality were reported in 2022. The rising number of such chronic conditions creates the demand for biologics, leading to the increased collaboration of pharmaceutical manufacturers with contract manufacturing organizations (CMOs) specialized in biologics manufacturing capabilities.
Biologics manufacturing is a complex process and requires highly specialized equipment, expertise, and facilities. The long production timelines and high costs associated with setting up in-house manufacturing facilities for biologics make outsourcing more crucial. CMOs provide the necessary infrastructure and expertise to scale production, allowing drug developers to meet market demand without any significant capital investment. Manufacturers such as Roche and Bristol-Myers Squibb have developed monoclonal antibody-based biologics, Herceptin and Opdivo, with the help of CMOs, which have transformed cancer treatments. These therapies have significantly increased the demand for contract manufacturing services as companies look for specialized facilities capable of producing these highly complex biologics on a large scale. Therefore, the rising demand for biologics has created the need for specialized, cost-effective, and scalable production solutions, fueling the growth of the biopharmaceutical contract manufacturing market.
Increasing Demand for Personalized Medicine to Create Growth Opportunities
Personalized medicine offers a significant opportunity by offering tailored treatments that are designed to meet the unique genetic profiles, environments, and lifestyles of individual patients. This approach is experiencing increased adoption owing to advancements in genomics, biotechnology, and diagnostics, allowing for more precise and effective treatments. The constant developments in personalized medicine are creating demand for specialized, flexible, and scalable manufacturing solutions. These developments have increased the collaborations with CMOs to bring these therapies to market. Personalized therapies often require tailored approaches that involve more flexible manufacturing processes, which include gene therapies, cell therapies, and precision oncology treatments. As a result, biopharmaceutical companies are increasingly turning to CMOs that offer the expertise and capacity to handle these specialized manufacturing needs.
The growing demand for personalized medicine emphasizes the need for efficient, scalable manufacturing processes that can adapt to the production of highly individualized treatments. For instance, gene therapies such as Kymriah (developed by Novartis) and Yescarta (from Gilead) are personalized medicines that have been successfully developed and commercialized. CMOs with the right infrastructure provide these treatments, as they require unique manufacturing processes. Moreover, CMOs that can offer specialized services for the production of cell-based therapies or gene-editing technologies, such as CRISPR-based treatments, are well-positioned to benefit from the personalized medicine trend. As companies move toward smaller batch sizes, flexibility, and customization, CMOs play a vital role in ensuring that these treatments are efficiently and cost-effectively produced, thereby creating lucrative opportunities for the market during the forecast period.
Biopharmaceutical Contract Manufacturing Market Report Segmentation Analysis
Key segments that are the foundation of biopharmaceutical contract manufacturing market analysis are product type, source, application, and therapeutic area.
- Based on product type, the biopharmaceutical contract manufacturing market is bifurcated into biologics and biosimilar. The biologics segment held a larger share of the market in 2024.
- In terms of source, the biopharmaceutical contract manufacturing market is categorized into microbial and mammalian. The microbial segment dominated the market in 2024.
- By application, the biopharmaceutical contract manufacturing market is segmented into commercial and clinical. The commercial segment held a larger share of the market in 2024.
- Per therapeutic area, the market is classified into oncology, autoimmune disorders, respiratory disorders, metabolic disorders, neurology, infectious diseases, and others. The oncology segment dominated the biopharmaceutical contract manufacturing market share in 2024.
Biopharmaceutical Contract Manufacturing Market Share Analysis by Geography
The geographic scope of the biopharmaceutical contract manufacturing market report is divided into five regions: North America, Asia Pacific, Europe, the Middle East & Africa, and South & Central America.
North America held a significant share of the market in 2024. The growth of the global biopharmaceutical contract manufacturing market in North America can be attributed to the well-established pharmaceutical industry, advanced technological infrastructure, and a strong regulatory framework that supports innovation and quality manufacturing. The US remains a dominant player due to its large pharmaceutical base, a high R&D investment, and the presence of significant contract development and manufacturing organizations (CDMOs). Canada is also expanding its capabilities, especially in niche biologics and sterile manufacturing. The growth in outsourcing trends among pharmaceutical companies reduces costs and accelerates time-to-market, further boosting the biopharmaceutical contract manufacturing market in the region.
Biopharmaceutical Contract Manufacturing Market Report Scope
Biopharmaceutical Contract Manufacturing Market News and Recent Developments
The biopharmaceutical contract manufacturing market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A key development in the market is listed below:
- Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche. (Source: Lonza, Press Release, October 2024)
- Sutro Biopharma and Boehringer Ingelheim BioXcellence collaboration: Established first-in-class cell-free capabilities at a commercial scale. (Source: Sutro Biopharma, Inc.; Press Release, January 2025)
- Boehringer Ingelheim enhances biopharmaceutical contract manufacturing services in China. (Source: Boehringer Ingelheim International GmbH, Press Release, March 2025)
Biopharmaceutical Contract Manufacturing Market Report Coverage and Deliverables
The "Biopharmaceutical Contract Manufacturing Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
- Biopharmaceutical contract manufacturing market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Biopharmaceutical contract manufacturing market trends and market dynamics, such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Biopharmaceutical contract manufacturing market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments in the biopharmaceutical contract manufacturing market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product; Service, and Source, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
North America dominated the market in 2024.
Rising demand for biologics and increasing demand for cost efficiency and flexibility contribute to market growth.
Boehringer Ingelheim International GmbH, Thermo Fisher Scientific Inc., Lonza Group AG, Merck KGaA, AbbVie Inc., General Electric Co, Samsung Biologics Co Ltd, WuXi Biologics Inc., Inno Bio Ventures Sdn Bhd, and Ajinomoto Co Inc. are among the key players operating in the biopharmaceutical contract manufacturing market.
The market is estimated to register a CAGR of 13.8% during the forecast period.
The market is expected to reach a value of US$ 101.05 billion by 2031.
The List of Companies - Biopharmaceutical Contract Manufacturing Market
- Boehringer Ingelheim International GmbH
- Thermo Fisher Scientific Inc
- Lonza Group AG
- Merck KGaA
- AbbVie Inc.
- General Electric Co
- Samsung Biologics Co Ltd
- WuXi Biologics Inc
- Inno Bio Ventures Sdn Bhd
- Ajinomoto Co Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Biopharmaceutical Contract Manufacturing Market
Jun 2025
Wound Closure Devices Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Sutures, Adhesives, Staplers, Strips, and Others), Wound Type (Chronic Wound and Acute Wound), End User (Hospitals, Clinics, Ambulatory Surgery Centers, and Others), and Geography
Jun 2025
Cell and Gene Therapy Contract Development and Manufacturing Organization Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Service Type (Drug Development and Manufacturing, Testing and Regulatory Services, and Others), Product Type (Gene Therapy and Cell Therapy), End User (Pharmaceutical Companies, Biopharmaceutical Companies, and Others), and Geography
Jun 2025
Pediatric Cardiology Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type (Transcatheter Heart Valves, Occlusion Devices, Catheters, Stents, Introducer Sheaths, and Others), Disease Indication (Congenital Heart Disease, Acquired Heart Disease, Arrhythmias, Cardiomyopathies, and Others), Surgical Procedure (Interventional Procedures, Heart Rhythm Management Procedures, and Others), End User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2025
Pharmaceutical Membrane Filters Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Technology (Microfiltration, Ultrafiltration, Reverse Osmosis and Nanofiltration), Design (Hollow Fiber, Spiral Wound, Tubular System and Plate and Frame), Material (Polyethersulfone (PES), Polysulfone (PS), Cellulose-Based Membranes, Polytetrafluoroethylene (PTFE), Polyvinyl Chloride (PVC), Polyacrylonitrile (PAN) and Others), End User (Pharmaceutical and Biotech Industries and CROs and CDMOs), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, South & Central America)
Jun 2025
ECG Devices Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Resting ECG and Stress ECG), Lead Type (12-Lead ECG, 3–6 Lead ECG, and Single Lead), Technology [Portable (Wired) ECG System and Wireless ECG System], End User (Hospital and Clinics, Ambulatory Surgical Centers, Cardiac Centers, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jun 2025
Surgical Laser Fiber Units Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Laser Type (CO2 Laser, Diode Laser, Erbium Laser, Nd:YAG Laser, Holmium Laser, Alexandrite Laser, and Others), Material (Silica-Based Fibers, Quartz Fibers, Polymer-Based Fibers, Multimode Fibers, and Others), Power (Low-Power Lasers, Medium-Power Lasers, and High-Power Lasers), Application (Urology, Dermatology, Gynecology, Cardiology, Neurology, Ophthalmology, Respiratory, Dentistry and Others), Wavelength (9,301 nm and above, 2,941–9,300 nm, and 1,441–2,940 nm, 821–1,440 nm, 710–820 nm, and below 710 nm), End User (Hospitals, Specialty Clinics, Physician Office, and Others), and Geography
Jun 2025
Therapeutic Vaccines Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Cancer Vaccines, Infectious Disease Vaccines, and Others), Technology (Allogenic Vaccines and Autologous Vaccines), End User (Hospitals, Clinics, and Others), and Geography
Jun 2025
Medical Cables Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Disposable Medical Cables, Reusable Medical Cables, and Custom Medical Cables), Applications [Diagnostics (Ultrasound Cables, Endoscopy Cables, Patient Interface Cables, and Others), Motorized Equipment, Patient Monitoring (ECG Cables, SpO2 Cables, NiBP Cables, EEG Cables, and Others), Surgical and Life Support (Fiber Optics, Modular Local Area Network, and Others), and Others], End User (Hospital and Clinics, Diagnostic Laboratories and Imaging Centers, Ambulatory Surgical Centers, and Others), and Geography